---All---
  • ---All---
  • Accession
  • Catalog #

Cystatin B AntibodyRabbit Monoclonal IgG

Country
United States
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others
Ordering Information
Catalog # Size Availability Price  
AJ1215a 100ul 400 ul 2-3 days $ 315.00 Add to cart
  • Specification
  • Citiations : 0
  • Reviews
  • Protocols
  • Backgrounds

Cystatin B Antibody - Product info

ApplicationWB, IHC
  • Applications Legend:
  • W=Western Blotting
  • IP=Immunoprecipitation
  • IHC-P=Immunohistochemistry (Paraffin)
  • IF-IC=Immunofluorescence (Immunocytochemistry)
  • F=Flow Cytometry
Primary AccessionP04080
ReactivityHuman, Rat
Clone NamesEPR3931
Calculated MW11140 Da
Gene ID 1476
Target/Specificity
A synthetic peptide corresponding to residues in human Cystatin B was used as an immunogen.
Dilution
WB~~1:1000~10000
IHC~~1:100~250
Format
50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions
Cystatin B Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Cystatin B Antibody - Protein Information

Name CSTB
Synonyms CST6, STFB
Function
This is an intracellular thiol proteinase inhibitor. Tightly binding reversible inhibitor of cathepsins L, H and B
Cellular Location
Cytoplasm. Nucleus.

Cystatin B Antibody - Related products

AP5089b: XRCC6 Antibody (C-term)

AP5089c: XRCC6 Antibody (Center)

AP6775a: Ku70 Antibody (N-term)

AP6775c: Ku70 Antibody (Center)

RI15763: XRCC6 predesign siRNA

LY10971a: XRCC6 Over-expression Lysate

BP5089b: XRCC6 Antibody (C-term) Blocking Peptide

BP5089c: XRCC6 Antibody (Center) Blocking peptide

BP6775a: Ku70 Antibody (N-term) Blocking Peptide

BP6775c: Ku70 Antibody (Center) Blocking Peptide

AT2136a: G22P1 Antibody (monoclonal) (M01)

AT4554a: XRCC6 Antibody (monoclonal) (M05)

AJ1215a: Cystatin B Antibody

AJ1215b: Cystatin B Antibody

AF1607a: KU70 / XRCC6 Antibody

Abgent welcomes feedback from its customers.

If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abgent.com.

Thank you for your support.


Submit

Provided below are standard protocols that you may find useful for product applications.

BACKGROUND

Cystatin B is a member of the cysteine protease inhibitor superfamily, functioning as an intracellular thiol protease inhibitor (1). It plays a role in protecting proteinases from lysosomal leakage (1, 2). The second hairpin loop and the C-terminal end of Cystatin B anchor the inhibitor to target proteinases (3). Cystatin B interacts with and inhibits proteases of the cathepsin family (4). A deficiency in cystatin B is observed in progressive myoclonic epilepsy type 1 (1). This deficiency predisposes neurons to oxidative stress that leads to neuronal death and degeneration (1). In addition, Cystatin B has been linked to amyloid fibril formation in vitro and is overexpressed in hepatocellular carcinoma (5, 6).

REFERENCES

1. Online Mendelian Inheritance in Man, OMIM (TM). Johns Hopkins U, Baltimore, MD. MIM Number: {601145}: {11/27/2006}: . WWW URL: http://www.ncbi.nlm.nih.gov/omim/ 2. Lehtinen MK et al. J Neurosci. 29(18):5910-5, 2009. 3. Pol E et al. Biochemistry. 38(32):10519-26, 1999. 4. Riccio M et al. Exp Cell Res. 262(2):84-94, 2001. 5. Zerovnik E et al. Biochim Biophys Acta. 1594(1):1-5, 2002. 6. Lee MJ et al. Clin Cancer Res. 14(4):1080-9, 2008.